Trial Profile
Phase II trial of PM 01183 as second-line therapy in patients with metastatic pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors PharmaMar
- 05 Oct 2021 Status changed from recruiting to completed.
- 29 Apr 2021 Results (N=244), Pharmacokinetic-pharmacodynamic analyses of pooled data from phase I studies A-0015 and A-005, and phase II studies B001, B-002, and B-0038 published in the Journal of Clinical Pharmacology
- 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.